Search
Research
Hypomethylation of the CTGF gene locus is a common feature of paediatric pre-B acute lymphoblastic leukaemiaWe identified consistent hypomethylation of the CTGF locus in primary pre-B ALL specimens regardless of CTGF expression.
Research
Analysis of tandem E-box motifs within human Complement receptor 2 (CR2/CD21) promoter reveals cell specific roles for RP58...Complement receptor 2 (CR2/CD21) plays an important role in the generation of normal B cell immune responses.
Research
The evolution of clinical trials for infant acute lymphoblastic leukemiaDespite initial improvements in survival of infants with ALL since establishment of the first pediatric cooperative group ALL trials, the poor outcome has...
Research
Drug-gene modeling in pediatric T-cell acute lymphoblastic leukemia highlights importance of 6-mercaptopurine for outcomeThis study advances our understanding of drug resistance in T-ALL and provides new markers for patient stratification.
Research
Fusionfinder: A software tool to identify expressed gene fusion candidates from RNA-seq dataThe hallmarks of many haematological malignancies and solid tumours are chromosomal translocations, which may lead to gene fusions.
Research
Novel non-TCR chromosome translocations t(3;11)(q25;p13) and t(X;11)(q25;p13) activating LMO2In T-cell acute lymphoblastic leukemia (T-ALL) cytogenetic alterations juxtapose the LIM-domain-only-2 gene (LMO2) with T-cell receptor loci.
Research
Returning raw genomic data to research participants in a pediatric cancer precision medicine trialIn pediatric cancer precision medicine clinical trials settings, parents proactively seeking treatment and answers to causation may request return of their child's raw data and/or biospecimen. To satisfy such requests, the ZERO Childhood Cancer Program required a guidance document.
Research
KMT2A-rearranged acute lymphoblastic leukaemiaKMT2A-rearranged acute lymphoblastic leukaemia (ALL) represents a high risk subtype of childhood ALL. Historical treatment strategies have comprised of intensification with conventional chemotherapy. However, outcomes have remained consistently poor compared to the advances that have been seen for other ALL subtypes, particularly for infants diagnosed before their first birthday